35676-70-1

Basic information

• Product Name: 2-Chloro-3-hydroxyquinoxaline
• Synonyms: 2-Chloro-3-hydroxyquinoxaline;3-Chloroquinoxalin-2-ol;3-chloro-1,2-dihydroquinoxalin-2-one;3-chloroquinoxalin-2(1H)-one
• CAS NO: 35676-70-1
• Molecular Formula: C₈H₅ClN₂O
• Molecular Weight: 180.5911
• Mol File: 35676-70-1.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 338.2°C at 760 mmHg
• Flash Point: 158.3°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 5.09E-05mmHg at 25°C
• Refractive Index: 1.688
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-Chloro-3-hydroxyquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-hydroxyquinoxaline(35676-70-1)
• EPA Substance Registry System: 2-Chloro-3-hydroxyquinoxaline(35676-70-1)

Safety Data

• Hazardous Substances Data: 35676-70-1(Hazardous Substances Data)

Usage

General Description

2-Chloro-3-hydroxyquinoxaline is a chemical compound with the molecular formula C8H6ClNO. It is a quinoxaline derivative and consists of a quinoxaline ring with a chlorine atom at position 2 and a hydroxyl group at position 3. 2-Chloro-3-hydroxyquinoxaline has potential biological activity and is used in pharmaceutical research for the development of new drugs. Its properties and structure make it a versatile building block for the synthesis of various organic compounds, and it is also used as an intermediate in the production of certain pesticides. Additionally, 2-Chloro-3-hydroxyquinoxaline has been studied for its potential antitumor and antimicrobial activities. Overall, this compound has various applications and is important in the field of medicinal and organic chemistry.

InChI:InChI=1/C8H5ClN2O/c9-7-8(12)11-6-4-2-1-3-5(6)10-7/h1-4H,(H,11,12)

Upstream product

• 15804-19-0 quinoxaline-2,3-dione 
• 2213-63-0 2,3-dichloroquinoxaline 
• 95-54-5 1,2-diamino-benzene 
• 1050514-29-8 2-[(dimethylamino)methyl]-1-methyl-1H-imidazole-4-sulfonamide 
• 49568-68-5 3-chloroquinoxaline-2-carboxaldehyde 
• 1196-57-2 quinoxalin-2⁽¹⁾-one 

Downstream Products

• 29067-85-4 4-hydroxytetrazolo[1,5-a]quinoxaline 
• 1374748-69-2 2-(3-((4-fluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-70-5 2-(3-((4-bromophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-71-6 2-(3-((4-bromo-2-fluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-72-7 2-(3-((2,4-difluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-73-8 2-(2-oxo-3-((3,4,5-trifluorophenyl)amino)quinoxalin-1(2H)-yl)acetic acid 
• 1374748-74-9 2-(3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid 
• 1374748-75-0 2-(3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)-acetic acid 
• 1374748-76-1 2-(3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetic acid 
• 1374748-48-7 methyl 2-(3-(4-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-49-8 methyl 2-(3-(4-bromophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-50-1 methyl 2-(3-(4-bromo-2-fluorophenoxy)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-45-4 methyl 2-(3-((4-bromo-2-fluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetate 
• 1374748-46-5 methyl 2-(3-((2,4-difluorophenyl)amino)-2-oxoquinoxalin-1(2H)-yl)acetate 

Relevant articles and documents

Structure, preparation method and application of quinoxalinone derivative

The invention provides a structure and preparation of a quinoxalinone derivative (a compound as shown in formula I) and application of the pharmaceutically acceptable salt of the quinoxalinone derivative in the preparation of drugs for preventing and/or treating diabetic complication. The quinoxalinone derivative serving as a aldose reductase inhibitor and antioxidant can prevent and/or treat thediabetic complication by inhibiting the activity of aldose reductase and effectively scavenging free radicals and lipid peroxide and inhibiting active oxygen at the same time.

Exploration of quinoxaline derivatives as antimicrobial and anticancer agents

Novel 2 and 3-substituted quinoxaline derivatives were synthesized through various synthetic pathways, among which cyanoacetamide and cyanoacetohydrazide quinoxaline derivatives 4a-c and 11a-c, respectively, were synthesized. Furthermore, methoxy quinoxaline derivatives 3c and quinoxaline derivatives bearing substituted pyridines 6a,b, 12a,b, and 13a,b were designed to be synthesized. However, we have synthesized acrylohydrazide 5a,b and 7/acrylamide derivatives, Schiff base analogues 14a-f, pyrazole derivatives 15a-e, amide derivatives 16a-f, guanidine derivatives 16 g,h as well as, quinoxalin-2-methylallyl propionate derivative 14g. All the synthesized compounds were confirmed via spectral data and elemental analyses. Moreover, the newly synthesized compounds were evaluated for their antimicrobial activity (Gm +ve, Gm ?ve in comparison to Gentamycin a standard) and fungi (in comparison to Ketoconazole as a standard). Thus, compound 16b showed promising antimicrobial activity against B. subtilis, P. vulgaris, and S. mutants with values ranging from 20 to 27-mm zone of inhibition. While compounds 5a, 14e,f, and 16a,c,d,g,h showed potent antimicrobial activity. Moreover, the National Cancer Institute (NCI) selected 20 compounds that were submitted for anticancer screening against 60 types of cancer cell lines. The most active compounds are 5b and 12a where compound 5b containing 2,4-dichlorophenyl moiety at cyanoacetamide linkage of hydrazine quinoxaline backbone exerted significant growth inhibition activity against Leukemia MOLT-4, Renal cancer UO-31, and Breast cancer MCF-7. In addition, compound 12a having 4,6-diaminopyridinone side chain at position-3 of quinoxaline nucleus exhibited remarkable anticancer activity against renal cancer UO-31.

Design, synthesis and structure-activity relationship of novel quinoxaline derivatives as cancer chemopreventive agent by inhibition of tyrosine kinase receptor

The cancer chemopreventive activity of quinoxaline derivatives 1-20 has been evaluated by studying the inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) activation. The quinoxaline derivatives 1-20 showed inhibitory effect on EBV-EA activation without cytotoxicity on Raji cells. All compounds exhibited dose dependent inhibitory activities, most of them showed significant activity at 1000 mol ratio/12-O-tetradecanoylphorbol-13-acetate (TPA). Compounds 7 and 9 exhibited stronger inhibitory effects on the EBV-EA activation than that of the representative control, oleanolic acid, at the highest measured concentration. In addition, compounds 7-10 showed potent and selective inhibition of human tyrosine kinase (TRK) in liver cancer HepG2 and breast cancer MCF-7 cell lines similar to the positive control, doxorubicin.